ADHD, Gut Problems and Synbiotic

Sponsor
Super Synbiotics AB
Study ID
NCT07717359
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • ADHD
  • Emotion Regulation Abilities
  • Gastrointestinal

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Not accepted

Interventions

  • Synbiotic Cap Gut-Brain — DIETARY_SUPPLEMENT
    Capsules (2 capsules to be ingested once daily during 12 weeks)
  • Placebo — OTHER
    Capsules (2 capsules to be ingested once daily during 12 weeks)

Study Details

The scope of this study is to evaluate the impact of a synbiotic product (a combination of probiotic bacteria and prebiotics) on symptoms reported by participants with ADHD. The main focus is to study the efficacy of the synbiotic product as compared to a placebo in improving emotion regulation and gut-health associated symptoms in adults with ADHD.

Key Dates

First listed
Jul 21, 2026
Start date
Sep 30, 2026
Status verified
May 2026
Primary completion
Oct 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
174 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Synbiotic Cap Gut-Brain
    Capsules containing the synbiotic product being evaluated. The product consists of a combination of probiotic bacteria (at a total dose of 15 x 10\^9 CFU/2 capsule), dietary fibers (120 mg), calcium and vitamin B. The participants will be instructed to consume 2 capsules once every day, during a period of 12 weeks.
  • Placebo Comparator: Placebo
    Capsules containing placebo consisting of maltodextrin. The capsules look, smell and taste the same as the capsules for the experimental product. The participants will be instructed to consume 2 capsules once every day, during a period of 12 weeks.

Primary Outcome Measure

Change from baseline in the total score of Difficulties Regulation Scale 16 (DERS-16) after 12 weeks of intervention. [ Time Frame: Change from baseline to 12 weeks ]

Central Contacts

Find similar trials

Nationwide
ADHD trialsPsychiatry trialsMental health trialsBehavioral health trials

Related Studies